This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Dilated cardiomyopathy울혈성 심근병증

ICD-10 codeI42.0
Special Copayment Reduction codeV289
Synonyms / related termsDilated cardiomyopathy (DCM), non-ischemic dilated cardiomyopathy, familial dilated cardiomyopathy, idiopathic dilated cardiomyopathy
ClassificationSevere intractable disease (Special Copayment Reduction registration criteria: 5 years)

History

Dilated cardiomyopathy (DCM; congestive cardiomyopathy) is a myocardial disease characterized by dilation of the left ventricle (or both ventricles) and reduced systolic function. Until the early 20th century, this group of diseases was described mainly as heart failure of alcoholic, viral, or unknown cause. In 1957, Brigden first systematized non-ischemic myocardial disease under the term "cardiomyopathy," and in the 1980 WHO/ISFC classification DCM was included as an official classification item.

The concept of familial DCM was established in 1992, when Michels et al. found ventricular dysfunction in 20% of families of patients with idiopathic DCM. Subsequently, with advances in molecular genetics, various causative genes such as TTN (titin), LMNA (lamin A/C), MYH7, and SCN5A were identified. Recently, new genes such as DYRK1B and RBM20 are being discovered as genetic causes of DCM.

In terms of treatment, ACE inhibitors in the 1980s, followed by beta-blockers (MERIT-HF, COPERNICUS studies), mineralocorticoid receptor antagonists (RALES study), and sodium-glucose cotransporter 2 (SGLT2) inhibitors (DAPA-HF, EMPEROR-Reduced studies) have contributed to reducing mortality.

Causes

The causes of DCM are divided into hereditary (familial/genetic) and non-hereditary (non-familial/acquired). Hereditary causes account for 20–35% of all DCM, and non-hereditary causes include viral infection (after myocarditis, especially parvovirus B19, adenovirus, enterovirus, HHV-6), alcohol, pregnancy (peripartum cardiomyopathy), anticancer drug toxicity (anthracyclines, Herceptin), autoimmunity (giant cell myocarditis, cardiac sarcoidosis, systemic lupus erythematosus), thyroid dysfunction, and takotsubo cardiomyopathy.

Chronic tachycardia-induced cardiomyopathy is an important cause in which reversible LV dysfunction is induced by uncontrolled tachycardia. Ischemic cardiomyopathy is classified separately in ICD-10, and I42.0 covers non-ischemic DCM without obvious coronary artery disease.

Idiopathic DCM is diagnosed after excluding known causes and accounts for about 50% or more of all DCM. There is also a recent concept that does not clearly separate hereditary and idiopathic forms and integrates them as "primary DCM."

Genetics

The gene accounting for the largest share of genetic variants in DCM is TTN (titin), with truncating variants identified in about 25% of all familial DCM and about 18% of idiopathic DCM. Titin is the largest protein of the sarcomere and contributes to myofiber elasticity and mechanosensing.

LMNA (lamin A/C) variants occur in about 5–8% of DCM and are accompanied by atrioventricular conduction disorders, atrial fibrillation, ventricular arrhythmias, and risk of sudden death, so prognosis is poor. For LMNA variant carriers, a lower threshold for ICD (implantable cardioverter-defibrillator) implantation is applied. SCN5A (Nav1.5) variants show a phenotype in which Brugada syndrome and conduction disorders coexist with DCM.

Other DCM-related genes: MYH7 (beta-myosin heavy chain), TNNT2 (cardiac troponin T), TNNI3 (troponin I), TPM1 (tropomyosin), ACTC1 (cardiac actin), PLN (phospholamban), DSP (desmoplakin), RBM20 (RNA-binding motif protein), FLNC (filamin C). Diagnosis is made by whole exome sequencing (WES) or a cardiomyopathy gene panel, and genetic counseling is needed to decide on testing of patients' family members.

Epidemiology

The prevalence of DCM is estimated at about 36–40 per 100,000 of the general population and the incidence at about 5–8 per 100,000 per year. About 30–35% of all heart failure is due to DCM, and it is a leading underlying disease for heart transplantation. It occurs about 3 times more often in men than in women, and the median age of onset is about 30–50 years.

Familial DCM is identified in about 20–35% of first-degree relatives of patients with idiopathic DCM, and the proportion is higher when asymptomatic-stage LV dysfunction (LV enlargement, mild EF reduction) is also included. Domestic epidemiology, based on health insurance claims data, shows that DCM accounts for the largest proportion of all cardiomyopathy patients.

DCM-related heart transplantation accounts for about 40–50% of all heart transplantation in Korea, and registration for Special Copayment Reduction (V289) reduces the treatment cost burden. The number of patients using mechanical circulatory support devices (LVAD, BiVAD) while awaiting transplantation is also increasing.

Pathophysiology

The core pathophysiology of DCM is reduced contractility due to cardiomyocyte injury or dysfunction and the resulting compensatory ventricular remodeling. The main mechanisms of cardiomyocyte injury are as follows.

Genetic mechanisms: Abnormalities of sarcomere proteins or nuclear envelope proteins disturb the mechanical function and signal transduction of cardiomyocytes. TTN variants cause decreased sarcomere stability, and LMNA variants cause abnormal nuclear mechanical stability and regulation of gene expression.

Neurohumoral activation: When cardiac output falls, the RAAS (renin-angiotensin-aldosterone system) and the sympathetic nervous system are compensatorily activated, and persistent activation forms a vicious cycle causing cardiomyocyte hypertrophy, fibrosis, and cell death. Angiotensin II and aldosterone are the main promoters of myocardial fibrosis.

Calcium dysregulation: Intracellular calcium overload (Ca2+ overload) in cardiomyocytes and reduced function of SR Ca2+-ATPase (SERCA2a) cause impaired excitation-contraction coupling. Mitochondrial dysfunction, oxidative stress, and inflammatory mediators (TNF-α, IL-1β, IL-6) accelerate cardiomyocyte death.

Symptoms

The clinical symptoms of DCM are predominantly those of heart failure. Symptoms of forward failure due to reduced left ventricular function: exercise intolerance, fatigue, and weakness. Symptoms of pulmonary congestion (backward failure): exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea (PND), and pulmonary edema.

With right heart failure: lower extremity edema (pitting edema), abdominal discomfort (ascites, hepatomegaly), jugular venous distension, and nocturia. Arrhythmia-related symptoms: palpitations, dizziness, presyncope, and sudden palpitations occur when atrial fibrillation or ventricular tachycardia develops.

Thromboembolism: stroke or peripheral embolism may occur from atrial fibrillation or intracardiac thrombus. In LMNA variant DCM, cardiac conduction disorders (atrioventricular block, sinus node dysfunction) appear as initial symptoms, and syncope or sudden cardiac death due to ventricular arrhythmia occurs at a higher frequency than in other DCM.

Signs

On physical examination, cardiomegaly (displaced and enlarged apical impulse, leftward displacement), abnormal heart sounds (S3, S4 gallop), a systolic murmur from mitral regurgitation, elevated jugular venous pressure, hepatojugular reflux (HJR), pitting edema of the lower extremities, and ascites may be observed.

Blood pressure: in advanced DCM, reduced pulse pressure and lowered systolic blood pressure are observed. Tachycardia (compensatory tachycardia or atrial fibrillation) and pulsus alternans (in severe heart failure) may appear. Chest auscultation: a holosystolic murmur of mitral regurgitation and crackles due to pulmonary congestion are characteristic.

Laboratory findings: markedly elevated BNP/NT-proBNP, hyponatremia (a poor prognostic factor), decreased renal function (cardiorenal syndrome), liver function abnormalities (congestive hepatopathy), and anemia may accompany. Electrocardiogram: sinus tachycardia, left bundle branch block (LBBB), nonspecific T-wave abnormalities, PR interval prolongation, QRS prolongation, and atrial fibrillation are commonly observed.

Screening

The electrocardiogram (ECG) is the initial screening test, evaluating rhythm abnormalities, conduction disorders, left ventricular hypertrophy, and ST-T changes. LBBB and QRS >150 ms suggest an indication for CRT (cardiac resynchronization therapy).

Serum biomarkers: BNP (>100 pg/mL) or NT-proBNP (>400 pg/mL) are key biomarkers for the diagnosis and severity of heart failure and for monitoring treatment response. Elevated cardiac troponin (cTnI, cTnT) suggests acute myocardial injury or progressive DCM. Thyroid function tests (TSH, fT4), iron studies (serum iron, TIBC, ferritin), CBC, and renal and liver function tests are included to exclude secondary causes and assess comorbidities.

ECG monitoring and 24-hour Holter: used to assess the risk of atrial fibrillation and ventricular tachycardia/fibrillation. Gene panel testing (DCM gene panel or WES) is recommended with a positive family history, an LMNA phenotype (with conduction disorder), age of onset under 60, or an atypical phenotype.

Diagnosis

The key to the diagnosis of DCM is echocardiography. Diagnostic criteria: left ventricular end-diastolic diameter > upper limit of normal (exceeding the sex- and height-adjusted value), left ventricular ejection fraction (LVEF) < 45–50%, and exclusion of other structural heart disease (coronary artery disease, congenital heart disease, valvular heart disease).

Cardiac MRI (CMR): used to evaluate the myocardial fibrosis (late gadolinium enhancement, LGE) pattern, myocardial inflammation (T1/T2 mapping), and for accurate measurement of ventricular function and volumes. Non-ischemic distribution LGE is important in DCM for predicting the risk of arrhythmia and death. Coronary angiography or coronary CT (CCTA) is performed to exclude ischemic cardiomyopathy.

Endomyocardial biopsy (EMB) is performed to determine specific treatment in giant cell myocarditis, cardiac sarcoidosis, or rapidly progressing heart failure. For Special Copayment Reduction (V289) registration, a diagnosis certificate from a cardiologist, echocardiography results (including the LVEF value), and CMR results if necessary are submitted.

Treatment

Drug treatment of heart failure with reduced ejection fraction (HFrEF, LVEF ≤ 40%) due to DCM is established as four pillar drugs: ① ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB), or ARNI (sacubitril/valsartan); ② beta-blocker (carvedilol, bisoprolol, metoprolol extended-release); ③ mineralocorticoid receptor antagonist (MRA; spironolactone, eplerenone); ④ SGLT2 inhibitor (dapagliflozin, empagliflozin).

Device therapy: an ICD is implanted to prevent sudden death when indicated at LVEF ≤ 35%, NYHA II–III, after 3 months of optimal drug therapy (a lower threshold applies, especially in LMNA variant DCM). CRT (or CRT-D) is considered to improve heart failure symptoms and prognosis in patients with LBBB, QRS ≥ 150 ms, and LVEF ≤ 35%.

In advanced heart failure, mechanical circulatory support devices (LVAD; as a bridge to heart transplantation or as destination therapy) and heart transplantation are the final treatment options. Diuretics (loop diuretics, thiazides) are used to control congestive symptoms but have no mortality-reducing effect. When iron deficiency is present, intravenous iron supplementation (ferric carboxymaltose) is effective for improving symptoms and exercise capacity.

Prognosis

The prognosis of DCM varies according to LVEF at diagnosis, NYHA functional class, and response to optimal drug therapy. After optimal drug therapy, LVEF recovers by 10% or more ("reverse remodeling") in about 30–40%, and in these cases the prognosis improves markedly. However, when LVEF remains persistently low, the 5-year mortality reaches 20–30%.

LMNA variant DCM has the worst prognosis, with a markedly higher risk of sudden death than other hereditary DCM. Ventricular tachycardia of 4% or more per year, non-sustained ventricular tachycardia, male sex, and the type of LMNA variant are poor prognostic factors. TTN variant DCM has a relatively better prognosis than LMNA.

The 5-year survival after heart transplantation is about 70–75%, and the 2-year survival in long-term LVAD users is about 60–70%. Regular outpatient follow-up (every 3–6 months), monitoring of echocardiographic LVEF, tracking of BNP, and checks of ICD/CRT devices are the key to long-term management.

Prevention

Primary prevention of DCM differs according to the cause. Alcoholic DCM: abstinence from alcohol is key to halting disease progression, and LVEF recovery is also possible with early abstinence. Anticancer drug-induced DCM: limiting the cumulative anthracycline dose, concurrent use of the cardioprotectant dexrazoxane, and echocardiographic follow-up before, during, and after treatment are recommended.

Familial DCM: first-degree relatives (parents, siblings, children) of confirmed patients should undergo echocardiographic and ECG screening regardless of symptoms (at 3–5-year intervals for adults). If abnormalities are found, early treatment is started. When a genetic diagnosis is made, genetic counseling and a follow-up plan are established for carrier relatives.

Lifestyle management: regular aerobic exercise (cardiac rehabilitation), a low-sodium diet, fluid restriction, avoiding heavy drinking, and smoking cessation help prevent worsening of heart failure. Influenza and pneumococcal vaccination prevents decline in cardiac function from infection-related worsening in heart failure patients. At the 5-year renewal of Special Copayment Reduction, the current LVEF, NYHA class, and treatment details are entered on the specialist confirmation form.

References

  1. Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice. Eur Heart J. 2016;37(23):1850-1858. PMID: 26819810
  2. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. PMID: 34447992
  3. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008. PMID: 31535829
  4. Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013;10(9):531-547. PMID: 23900355
  5. Herman DS, Lam L, Taylor MR, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012;366(7):619-628. PMID: 22335739
  6. van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers a European cohort study. J Am Coll Cardiol. 2012;59(5):493-500. PMID: 22281253
  7. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651-1658. PMID: 11386263
  8. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21. PMID: 21073363
  9. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342(15):1077-1084. PMID: 10760308
  10. Kim JH, Sung JD, Choe KH, et al. Causes and outcomes of dilated cardiomyopathy in Korean patients. J Korean Med Sci. 2012;27(10):1185-1190. DOI: 10.3346/jkms.2012.27.10.1185